Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Fregni, Chiara Silacci"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Collier, Dami A, De Marco, Anna, Ferreira, Isabella ATM, Meng, Bo, Datir, Rawlings, Walls, Alexandra C, Kemp S, Steven A, Bassi, Jessica, Pinto, Dora, Fregni, Chiara Silacci, Bianchi, Siro, Tortorici, M Alejandra, Bowen, John, Culap, Katja, Jaconi, Stefano, Cameroni, Elisabetta, Snell, Gyorgy, Pizzuto, Matteo S, Pellanda, Alessandra Franzetti, Garzoni, Christian, Riva, Agostino, CITIID-NIHR BioResource COVID-19 Collaboration, Elmer, Anne, Kingston, Nathalie, Graves, Barbara, McCoy, Laura E, Smith, Kenneth Gc, Bradley, John R, Temperton, Nigel, Ceron-Gutierrez L, Lourdes, Barcenas-Morales, Gabriela, COVID-19 Genomics UK (COG-UK) Consortium, Harvey, William, Virgin, Herbert W, Lanzavecchia, Antonio, Piccoli, Luca, Doffinger, Rainer, Wills, Mark, Veesler, David, Corti, Davide, Gupta, Ravindra K
Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) transmission is uncontrolled in many parts of the world, compounded in some areas by higher transmission potential of the B1.1.7 variant now seen in 50 countries. It is unclear whether resp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d56835c80bddba9a96570141c999425f
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Piccoli Luca, Campo Ilaria, Fregni Chiara Silacci, Rodriguez Blanca Maria Fernandez, Minola Andrea, Sallusto Federica, Luisetti Maurizio, Corti Davide, Lanzavecchia Antonio
Publikováno v:
Nature Communications, 6
Nature Communications
Nature Communications
Pulmonary alveolar proteinosis (PAP) is a severe autoimmune disease caused by autoantibodies that neutralize GM-CSF resulting in impaired function of alveolar macrophages. In this study, we characterize 21 GM-CSF autoantibodies from PAP patients and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4bcff9ce6bae96d335ec5a6671f83b56
https://hdl.handle.net/20.500.11850/102531
https://hdl.handle.net/20.500.11850/102531
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Collier DA; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK.; Department of Medicine, University of Cambridge, Cambridge, UK.; Division of Infection and Immunity, University College London, London, UK., De Marco A; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland., Ferreira IATM; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK.; Department of Medicine, University of Cambridge, Cambridge, UK., Meng B; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK.; Department of Medicine, University of Cambridge, Cambridge, UK., Datir R; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK.; Department of Medicine, University of Cambridge, Cambridge, UK.; Division of Infection and Immunity, University College London, London, UK., Walls AC; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA., Kemp S SA; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK.; Department of Medicine, University of Cambridge, Cambridge, UK.; Division of Infection and Immunity, University College London, London, UK., Bassi J; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland., Pinto D; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland., Fregni CS; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland., Bianchi S; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland., Tortorici MA; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA., Bowen J; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA., Culap K; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland., Jaconi S; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland., Cameroni E; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland., Snell G; Vir Biotechnology, San Francisco, CA 94158, USA., Pizzuto MS; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland., Pellanda AF; Clinic of Internal Medicine and Infectious Diseases, Clinica Luganese Moncucco, 6900 Lugano, Switzerland., Garzoni C; Clinic of Internal Medicine and Infectious Diseases, Clinica Luganese Moncucco, 6900 Lugano, Switzerland., Riva A; Division of Infectious Diseases, Luigi Sacco Hospital, University of Milan, Milan, Italy., Elmer A; NIHR Cambridge Clinical Research Facility, Cambridge, UK., Kingston N; NIHR Bioresource, Cambridge, UK., Graves B; NIHR Bioresource, Cambridge, UK., McCoy LE; Division of Infection and Immunity, University College London, London, UK., Smith KG; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK.; Department of Medicine, University of Cambridge, Cambridge, UK., Bradley JR; Department of Medicine, University of Cambridge, Cambridge, UK.; NIHR Bioresource, Cambridge, UK., Temperton N; University of Kent, Canturbury, UK., Ceron-Gutierrez L L; Department of Clinical Biochemistry and Immunology, Addenbrookes Hospital, UK., Barcenas-Morales G; Department of Clinical Biochemistry and Immunology, Addenbrookes Hospital, UK.; Laboratorio de Inmunologia, S-Cuautitlán, UNAM, Mexico., Harvey W; Institute of Biodiversity, University of Glasgow, Glasgow, UK., Virgin HW; Vir Biotechnology, San Francisco, CA 94158, USA., Lanzavecchia A; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland., Piccoli L; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland., Doffinger R; Department of Clinical Biochemistry and Immunology, Addenbrookes Hospital, UK., Wills M; Department of Medicine, University of Cambridge, Cambridge, UK., Veesler D; Department of Biochemistry, University of Washington, Seattle, WA 98195, USA., Corti D; Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland., Gupta RK; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK.; Department of Medicine, University of Cambridge, Cambridge, UK.; University of KwaZulu Natal, Durban, South Africa.; Africa Health Research Institute, Durban, South Africa.; Department of Infectious Diseases, Cambridge University Hospitals NHS Trust, Cambridge UK.
Publikováno v:
MedRxiv : the preprint server for health sciences [medRxiv] 2021 Feb 15. Date of Electronic Publication: 2021 Feb 15.
Autor:
McCallum M, Marco A, Lempp F, Tortorici MA, Pinto D, Walls AC, Beltramello M, Chen A, Liu Z, Zatta F, Zepeda S, di Iulio J, Bowen JE, Montiel-Ruiz M, Zhou J, Rosen LE, Bianchi S, Guarino B, Fregni CS, Abdelnabi R, Caroline Foo SY, Rothlauf PW, Bloyet LM, Benigni F, Cameroni E, Neyts J, Riva A, Snell G, Telenti A, Whelan SPJ, Virgin HW, Corti D, Pizzuto MS, Veesler D
Publikováno v:
BioRxiv : the preprint server for biology [bioRxiv] 2021 Jan 14. Date of Electronic Publication: 2021 Jan 14.